论文部分内容阅读
本文用自身比较观察非诺贝特 2 0 0 mg每晚 1次 ,持续 6周治疗老年人高脂血症的疗效和耐受性。 42例均为男性 ,年龄 6 0～ 83岁 ,其中属高脂血症 型 32例 , b型 10例。治疗 6周后 , 型和 b型患者血清甘油三脂分别降低 5 1%和 41% (P<0 .0 1)。 b型患者血清总胆固醇降低 18% (P<0 .0 1) , 型患者无降低。两组患者服药 6周后高密度脂蛋白均有明显升高 (P<0 .0 1) ,载脂蛋白 B均有不同程度下降 (P<0 .0 5及 P<0 .0 1)。服药期间未见严重不良反应。提示微粒化非诺贝特可作为老年人 型及 b型高脂血症的首选药物。
This article compared with their own observation fenofibrate 200 mg once night, for 6 weeks treatment of elderly patients with hyperlipidemia efficacy and tolerance. 42 cases were male, aged 60 to 83 years, of which 32 cases were hyperlipidemia, b type 10 cases. After 6 weeks of treatment, serum triglycerides decreased by 51% and 41%, respectively (P <0.01). Type b patients with serum total cholesterol decreased by 18% (P <0. 01), type of patients without reduction. High-density lipoprotein was significantly increased in both groups after 6 weeks of treatment (P <0.01), while apolipoprotein B was decreased in varying degrees (P <0.05 and P <0.01). No serious adverse reactions during the medication. Tip micronized fenofibrate can be used as the elder type and type b hyperlipidemia drug of choice.